# Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)

> **NCT03829306** · — · COMPLETED · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 32 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03829306
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-12
- **Primary completion:** 2022-06-21
- **Final completion:** 2022-06-21
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829306, "Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT03829306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*